Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07053384 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

A Phase 1 study of HIV Infections, sponsored by ViiV Healthcare.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
20
Study locations

NCT07053384 is a Phase 1 study of HIV Infections that is actively recruiting participants, run by ViiV Healthcare. The registered enrollment target is 100 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07053384, a Phase 1 study of HIV Infections, is actively recruiting participants, sponsored by ViiV Healthcare.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2).

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL VH3810109
  • DRUG Fostemsavir (FTR)
  • DRUG SOC INSTI-based ART

Study Locations (20)

Other

  • GSK Investigational Site - Brussels
  • GSK Investigational Site - Ghent
  • GSK Investigational Site - Aarhus
  • GSK Investigational Site - Hvidovre
  • GSK Investigational Site - Rotterdam
  • GSK Investigational Site - Barcelona
  • GSK Investigational Site - Barcelona

California

  • GSK Investigational Site - Bakersfield
  • GSK Investigational Site - San Diego

Florida

  • GSK Investigational Site - Ft. Pierce
  • GSK Investigational Site - Orlando

Missouri

  • GSK Investigational Site - Kansas City
  • GSK Investigational Site - St Louis

Pennsylvania

  • GSK Investigational Site - Philadelphia
  • GSK Investigational Site - Pittsburgh

Texas

  • GSK Investigational Site - Dallas
  • GSK Investigational Site - Dallas

Illinois

  • GSK Investigational Site - Chicago

New York

  • GSK Investigational Site - New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-07-10
Est. Completion 2028-03-24
Phase Phase 1

Sponsor

ViiV Healthcare

182 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07053384

The ClinicalTrials.gov registry entry for NCT07053384 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which VH3810109 is the first listed.

NCT07053384 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT07053384 about?

NCT07053384 is a clinical study titled "A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV". This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase str...

What is the current status of trial NCT07053384?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-07-10. Estimated completion is 2028-03-24.

What conditions does trial NCT07053384 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT07053384?

The interventions under investigation include: VH3810109 (BIOLOGICAL), Fostemsavir (FTR) (DRUG), SOC INSTI-based ART (DRUG).

Who is sponsoring clinical trial NCT07053384?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07053384 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.